Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour

Documenti analoghi

• Durable response with a combination of imatinib and sorafenib in KIT exon 17 mutant gastrointestinal stromal tumor
  di: Singeltary, Brian, et al.
  Pubblicazione: (2014)
• Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report
  di: Engin, Gulgun, et al.
  Pubblicazione: (2017)
• Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
  di: Incorvaia, Lorena, et al.
  Pubblicazione: (2021)
• Imatinib as adjuvant treatment following resection of KIT-positive gastrointestinal stromal tumours
  di: J Dretzke, et al.
  Pubblicazione: (2010-10-01)
• Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations
  di: Kentaro Miyake, et al.
  Pubblicazione: (2018-06-01)